IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.

IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.
复制标题

DOI:
10.4155/fmc.13.90
复制
发表时间:
2013-06
影响因子:
4.2
通讯作者:
Podgorski I
Podgorski I
中科院分区:
医学3区
文献类型:
--
作者:
Hardaway AL;Podgorski I

文献摘要

参考文献

被引文献

相似文献

在过去的十年中,炎症和脂质介质,如IL-1β,FABP 4和TNF-α,已成为代谢功能障碍的重要贡献者。随着越来越多的实验和临床证据继续将肥胖诱导的慢性炎症与失调的脂质、胰岛素信号传导和相关病理联系起来,IL-1β、FABP 4和IL-10各自独立地被认为是这些事件的罪魁祸首。也有令人信服的数据表明,由这些分子驱动的分子途径在加剧肥胖的代谢后果中相互关联。这篇文章强调了IL-1β,FABP 4和IL-10在正常生理学中的作用,并特别关注它们对炎症,胰岛素抵抗,动脉粥样硬化,2型糖尿病和癌症的贡献。还讨论了涉及这些途径,当前和新兴疗法之间的相互联系的研究,以及它们作为潜在生物标志物的用途。IL-1β、FABP 4和TNF途径对代谢功能障碍严重程度的影响的证据强调了炎症事件、脂质代谢和胰岛素调节之间的密切联系,并为肥胖驱动的病理的未来治疗提供了新的有趣方法。
Within the past decade, inflammatory and lipid mediators, such as IL-1β, FABP4 and RAGE, have emerged as important contributors to metabolic dysfunction. As growing experimental and clinical evidence continues to tie obesity-induced chronic inflammation with dysregulated lipid, insulin signaling and related pathologies, IL-1β, FABP4 and RAGE each are being independently implicated as culprits in these events. There are also convincing data that molecular pathways driven by these molecules are interconnected in exacerbating metabolic consequences of obesity. This article highlights the roles of IL-1β, FABP4 and RAGE in normal physiology as well as focusing specifically on their contribution to inflammation, insulin resistance, atherosclerosis, Type 2 diabetes and cancer. Studies implicating the interconnection between these pathways, current and emerging therapeutics, and their use as potential biomarkers are also discussed. Evidence of impact of IL-1β, FABP4 and RAGE pathways on severity of metabolic dysfunction underlines the strong links between inflammatory events, lipid metabolism and insulin regulation, and offers new intriguing approaches for future therapies of obesity-driven pathologies.
DOI: 10.2337/db09-1199
发表时间: 2010-05
期刊: Diabetes
影响因子: 7.7
作者:
Carstensen M;Herder C;Kivimäki M;Jokela M;Roden M;Shipley MJ;Witte DR;Brunner EJ;Tabák AG
通讯作者: Tabák AG
DOI: 10.1007/s11060-012-0853-0
发表时间: 2012-07-01
影响因子: 3.9
作者:
Anghileri, Elena;Eoli, Marica;Finocchiaro, Gaetano
通讯作者: Finocchiaro, Gaetano
DOI: 10.1073/pnas.0902745106
发表时间: 2009-04-28
影响因子: 11.1
作者:
Ben-Sasson, Shlomo Z.;Hu-Li, Jane;Paul, William E.
通讯作者: Paul, William E.
DOI: 10.1186/1475-2840-11-72
发表时间: 2012-06-18
影响因子: 9.3
作者:
Aragonès G;Saavedra P;Heras M;Cabré A;Girona J;Masana L
通讯作者: Masana L
DOI: 10.1158/0008-5472.can-07-2354
发表时间: 2007-10-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Bunt, Stephanie K.;Yang, Linglin;Ostrand-Rosenberg, Suzanne
通讯作者: Ostrand-Rosenberg, Suzanne